Multivariate survival analysis of the patients with recurrent endometrial cancer

Journal of Gynecologic Oncology

Volumn 22, Issue 1, 2011, Pages 3-8

  Odagiri, Tetsuji ^a   Watari, Hidemichi ^a   Hosaka, Masayoshi ^a   Mitamura, Takashi ^a   Konno, Yousuke ^a   Kato, Tatsuya ^a   Kobayashi, Noriko ^a   Sudo, Satoko ^a   Takeda, Mahito ^a   Kaneuchi, Masanori ^a   Sakuragi, Noriaki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endometrial cancer; Multivariate analysis; Prognostic factor; Recurrence

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PELVIS LYMPHADENECTOMY; PERITONEUM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADICAL HYSTERECTOMY; RECURRENCE RISK; RECURRENT CANCER; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SURVIVAL RATE;

EID: 79954542359     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2011.22.1.3     Document Type: Article

References (19)

1. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 2003;83 Suppl 1:79-118.
2. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgicalpathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
3. Hirahatake K, Hareyama H, Sakuragi N, Nishiya M, Makinoda S, Fujimoto S. A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol 1997;65:82-7.
4. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44.
5. Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol 2005;96:651-7.
6. Watari H, Mitamura T, Moriwaki M, Hosaka M, Ohba Y, Sudo S, et al. Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy. Int J Gynecol Cancer 2009;19:1585-90.
7. Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol 2006;4:459-68.
8. Nishiya M, Sakuragi N, Hareyama H, Ebina Y, Furuya M, Oikawa M, et al. Cox multivariate regression models for estimating prognosis of patients with endometrioid adenocarcinoma of the uterine corpus who underwent thorough surgical staging. Int J Cancer 1998;79:521-5.
9. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 1987;60(8 Suppl):2035-41.
10. Karagol H, Saip P, Uygun K, Kucucuk S, Aydiner A, Topuz E. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma. Med Oncol 2006;23:543-8.
11. Sartori E, Laface B, Gadducci A, Maggino T, Zola P, Landoni F, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer 2003;13:458-65.
12. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol 2007;62:28-34.
13. Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010;28(18 Suppl):LBA1.
14. Watari H, Xiong Y, Hassan MK, Sakuragi N. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol 2009;112:229-34.
15. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005;11:7243-54.
16. Espinoza I, Lupu R. Cyr61 expression promotes taxol resistance: a molecular link with p53 in breast. Cancer Res 2009;69(24 Suppl):Abstract nr 1139.
17. Campagnutta E, Giorda G, De Piero G, Sopracordevole F, Visentin MC, Martella L, et al. Surgical treatment of recurrent endometrial carcinoma. Cancer 2004;100:89-96.
18. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375:1165-72.
19. Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:11-8.